The metabolism of bradykinin: a cornerstone for the understanding of the cardiovascular effects of metallopeptidase inhibitors.
The development of a sensitive and specific analytical approach for the quantification of bradykinin (BK) has enabled the identification of five metallopeptidases primarily responsible for the metabolism of BK, including angiotensin-converting enzyme (ACE) and neutral endopeptidase 24.11. Several metabolic studies have shown that the metallopeptidases that participate in BK metabolism vary by location (eg, plasma, endothelium or cardiomyocytes) and by pathology (eg, diabetes, myocardial infarction or left ventricular hypertrophy). These studies advance understanding of the role of endogenous BK in the cardiovascular effects of ACE inhibitors and other metallopeptidase inhibitors.
Adam
A
A
Université de Montréal, Montréal, Canada. albert.adam@umontreal.ca
Dumoulin
M J
MJ
Lamontagne
D
D
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001920:Bradykinin / Q000378:metabolism*; D003327:Coronary Disease / Q000188:drug therapy / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000378:metabolism; D006801:Humans; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D009206:Myocardium / Q000166:cytology
D000806:Angiotensin-Converting Enzyme Inhibitors; D008666:Metalloendopeptidases; D001920:Bradykinin